PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35244188-0	2022	DYRK1A suppression attenuates HIF-1alpha accumulation and enhances the anti-liver cancer effects of regorafenib and sorafenib under hypoxic conditions.	Sorafenib	116-125	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	0-6	
35244188-10	2022	Furthermore, DYRK1A knockdown could significantly enhance the anti-liver cancer effects of regorafenib and sorafenib under hypoxia.	Sorafenib	107-116	dual specificity tyrosine phosphorylation regulated kinase 1A	Homo sapiens	13-19